Financial Metrics Check: Lexicon Pharmaceuticals Inc (LXRX)’s Ratios for Trailing Twelve Months

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

As of close of business last night, Lexicon Pharmaceuticals Inc’s stock clocked out at $0.77, down -10.86% from its previous closing price of $0.86. In other words, the price has decreased by -$10.86 from its previous closing price. On the day, 6.63 million shares were traded. LXRX stock price reached its highest trading level at $0.8552 during the session, while it also had its lowest trading level at $0.75.

Ratios:

To gain a deeper understanding of LXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.43 and its Current Ratio is at 7.45. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.59.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 17, 2024, initiated with a Buy rating and assigned the stock a target price of $10.

On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.

On March 07, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $3.Jefferies initiated its Hold rating on March 07, 2023, with a $3 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’24 when COATS LONNEL bought 300,000 shares for $1.60 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 276975168 and an Enterprise Value of 118501168. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.96 while its Price-to-Book (P/B) ratio in mrq is 1.55. Its current Enterprise Value per Revenue stands at 22.662 whereas that against EBITDA is -0.563.

Stock Price History:

The Beta on a monthly basis for LXRX is 1.04, which has changed by -0.4166667 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, LXRX has reached a high of $3.73, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -18.65%, while the 200-Day Moving Average is calculated to be -51.60%.

Shares Statistics:

It appears that LXRX traded 4.40M shares on average per day over the past three months and 3819040 shares per day over the past ten days. A total of 361.49M shares are outstanding, with a floating share count of 168.72M. Insiders hold about 53.33% of the company’s shares, while institutions hold 29.65% stake in the company. Shares short for LXRX as of 1734048000 were 31277836 with a Short Ratio of 7.62, compared to 1731628800 on 31378261. Therefore, it implies a Short% of Shares Outstanding of 31277836 and a Short% of Float of 19.189999999999998.

Earnings Estimates

As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.08 and low estimates of -$0.17.

Analysts are recommending an EPS of between -$0.61 and -$0.76 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.5, with 5.0 analysts recommending between -$0.31 and -$0.65.

Revenue Estimates

In the current quarter, 6 analysts expect revenue to total $6.48M. It ranges from a high estimate of $26.7M to a low estimate of $2M. As of the current estimate, Lexicon Pharmaceuticals Inc’s year-ago sales were $702kFor the next quarter, 6 analysts are estimating revenue of $3.05M. There is a high estimate of $4.45M for the next quarter, whereas the lowest estimate is $2.1M.

A total of 6 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $31.3M, while the lowest revenue estimate was $6.5M, resulting in an average revenue estimate of $11.13M. In the same quarter a year ago, actual revenue was $1.2MBased on 6 analysts’ estimates, the company’s revenue will be $13.33M in the next fiscal year. The high estimate is $38.08M and the low estimate is $4.9M.

Most Popular